



Suggested Reading

Session 1

Augusto JB, Davies RH, Bhuva AN, et al. Diagnosis and risk stratification in hypertrophic cardiomyopathy using machine learning wall thickness measurement: a comparison with human test-retest performance.

<https://pubmed.ncbi.nlm.nih.gov/33735065/>

Balaji S, DiLorenzo MP, Fish FA, et al. Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: An international multicenter study. *Heart Rhythm*. October 2019. <https://pubmed.ncbi.nlm.nih.gov/31026510/>

Butler J, Hamo CE, Udelson JE, et al. Exploring new endpoints for patients with heart failure with preserved ejection fraction. *Circ Heart Fail*. November 2016.

<https://pubmed.ncbi.nlm.nih.gov/27756791/>

Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. *J Am Coll Cardiol*. June 2020.

<https://pubmed.ncbi.nlm.nih.gov/32466879/>

Mearini G, Stimpel D, Geertz B, et al. Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice. *Nat Commun*. December 2014.

<https://pubmed.ncbi.nlm.nih.gov/25463264/>

Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. September 2020. <https://pubmed.ncbi.nlm.nih.gov/32871100/>

Ommen S, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. December 2020.

<https://pubmed.ncbi.nlm.nih.gov/33229116/>

Saberi S, Wheeler M, Bragg-Gresham J, et al. Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy: A randomized clinical trial. *JAMA*. April 2017.

<https://pubmed.ncbi.nlm.nih.gov/28306757/>

Weng Z, Yao J, Chan RH, et al. Prognostic value of LGE-CMR in HCM: A meta-analysis. *JACC Cardiovasc Imaging*. December 2016. <https://pubmed.ncbi.nlm.nih.gov/27450876/>

Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *J Am Coll Cardiol*. August 2017.

<https://pubmed.ncbi.nlm.nih.gov/28461007/>



Session 2

Eberly LA, Day SM, Ashley EA, et al. Association of race with disease expression and clinical outcomes among patients with hypertrophic cardiomyopathy. *JAMA Cardiol*. January 2020.

<https://pubmed.ncbi.nlm.nih.gov/31799990/>

Gurwitz JH, Maurer MS. Tafamidis. A pricey therapy for a not-so-rare condition. *JAMA Cardiol*. March 2020. <https://pubmed.ncbi.nlm.nih.gov/31913401/>

Joynt Maddox K, Bleser WK, Crook HL, et al. American Heart Association value-based models learning collaborative. Advancing value-based models for heart failure: A call to action from the value in healthcare initiative's value-based models learning collaborative. *Circ Cardiovasc Qual Outcomes*. May 2020. <https://pubmed.ncbi.nlm.nih.gov/32393125/>

Lakdawala NK, Olivotto I, Day SM, et al. Associations between female sex, sarcomere variants, and clinical outcomes in hypertrophic cardiomyopathy. *Circ Genom Precis Med*. February 2021.

<https://pubmed.ncbi.nlm.nih.gov/33284039/>

Manrai AK, Funke BH, Rehm HL, et al. Genetic misdiagnoses and the potential for health disparities. *N Engl J Med*. August 2016. <https://pubmed.ncbi.nlm.nih.gov/27532831/>

Sheikh N, Papadakis M, Panoulas VF, et al. Comparison of hypertrophic cardiomyopathy in Afro-Caribbean versus white patients in the UK. *Heart*. November 2016.

<https://pubmed.ncbi.nlm.nih.gov/27679836/>

Srinivasan D, Desai NR. The impact of the transition from volume to value on heart failure care: Implications of novel payment models and quality improvement initiatives. *J Card Fail*. August 2017.

<https://pubmed.ncbi.nlm.nih.gov/28647442/>

Thomas A, Papoutsidakis N, Spatz E, et al. Access and outcomes among hypertrophic cardiomyopathy patients in a large integrated health system. *J Am Heart Assoc*. February 2020.

<https://pubmed.ncbi.nlm.nih.gov/31973610/>

Wells S, Rowin EJ, Bhatt V, et al. Association between race and clinical profile of patients referred for hypertrophic cardiomyopathy. *Circulation*. May 2018. <https://pubmed.ncbi.nlm.nih.gov/29712699/>

Yancy CW, Wang TY, Ventura HO, et al. The coalition to reduce racial and ethnic disparities in cardiovascular disease outcomes (credo): why credo matters to cardiologists. *J Am Coll Cardiol*. January 2011.

<https://pubmed.ncbi.nlm.nih.gov/21232662/>